Board of Directors

Dr. Charles Woler. Chairman & co-founder. Charles is Chairman of the Board, President and Chief Executive Officer of Endotis Pharma SA. Prior to joining the Company, he held positions of Chairman & CEO of Hofmann-La Roche (France), Chairman Europe Pharmaceuticals SB (London), CEO Cadus Pharmaceutical (Nasdaq-USA). He also was Executive Vice-Chairman of France Biotech, Non-Executive Director & Member of the Executive Committee at Imclone Systems (USA) and Chairman of the Board of Proclif Group (French private hospital chain). Charles, former co-founder and CEO of NEURO 3D (France), is currently Operating Partner Healthcare at Duke Street Capital, Vice-Chairman of the Board at Genfit (France), Chairman of the Board of Biomnis – France (esoteric blood testing). He is also Chairman of the Investment Committee of Inserm Transfert Initiative (France). He holds a MD degree from Paris University, a Ph.D. from Lyon University and a MBA

Dr. Philippe Meuwly, co-founder, is CEO and co-founder of Pharmalp SA. Philippe was the former Deputy General Manager of OM Pharma, a Swiss-based international bio-pharmaceutical company (500 collaborators worldwide) having successfully developed and commercialized medication of natural origin (representing CHF 70 million CHF in sales, 60% of total sales of the company). At OM Pharma, he established a company wide program management approach leading to the implementation of standardized, company wide project management methods and practices (yearly 25-30 projects worth CHF 60-80 millions and involving overall 50-70 people). This included working in a multicultural environment to lead the Mid-Term Plan of the group. Philippe has 15 years of experience in the pharma/biotech industry and graduated B.Sc. and PhD in Biology from the University of Lausanne and holds a post-graduate degree in business management from HEC Lausanne.

Mr. Levon Khachaturyan, member of the BoD, was deputy general director and contract manager at the Media Holding “E-Media”. Levon was then deputy head of investment banking department, responsible for M&A deals at Nord Capital Group (www.ncapital.ru). More recently, he became representative of BO, member of the board at various companies within the group, project manager at CJSC Investment Company (Imbera). He has a 10 years experience in private equity and M&A deals in Russia and in Europe.

Mr. Marsel Siraev, member of the BoD, is an Investment Manager at Waarde Capital, a private equity and venture capital firm with global outlook. At Waarde, Marsel is responsible for origination and execution of investments in the fields of industrial technologies, cleantech, robotics, aerospace and other industries. Prior to Waarde Capital, Marsel worked as an Analyst in the Investment Department of Basic Element, a diversified industrial group made up of over 100 Russian and international companies and facilities operating in a range of sectors. Marsel graduated from Bauman Moscow State Technical University.